A conserved neutralizing epitope on gp41 of human immunodeficiency virus type 1

T Muster, F Steindl, M Purtscher, A Trkola… - Journal of …, 1993 - Am Soc Microbiol
T Muster, F Steindl, M Purtscher, A Trkola, A Klima, G Himmler, F Rüker, H Katinger
Journal of virology, 1993Am Soc Microbiol
Vaccination against human immunodeficiency virus type 1 (HIV-1) requires an immunogen
which will elicit a protective immunity against viruses that show a high degree of genetic
polymorphism. Therefore, the identification of neutralizing epitopes which are shared by
many strains would be useful. In previous studies, we established a human monoclonal
antibody (2F5) that neutralizes a variety of laboratory strains and clinical isolates of HIV-1. In
the present report, we define the amino acid sequence Glu-Leu-Asp-Lys-Trp-Ala (ELDKWA) …
Vaccination against human immunodeficiency virus type 1 (HIV-1) requires an immunogen which will elicit a protective immunity against viruses that show a high degree of genetic polymorphism. Therefore, the identification of neutralizing epitopes which are shared by many strains would be useful. In previous studies, we established a human monoclonal antibody (2F5) that neutralizes a variety of laboratory strains and clinical isolates of HIV-1. In the present report, we define the amino acid sequence Glu-Leu-Asp-Lys-Trp-Ala (ELDKWA) on the ectodomain of gp41 as the epitope recognized by this antibody. The sequence was found to be conserved in 72% of otherwise highly variable HIV-1 isolates. Escape mutants were not detected in cells infected with HIV-1 isolates MN and RF in the presence of antibody 2F5. Since sequence variability of neutralizing epitopes is considered to be a major obstacle to HIV-1 vaccine development, the conserved B-cell epitope described here is a promising candidate for inclusion in a vaccine against AIDS.
American Society for Microbiology